Deal Watch: Best Value For Smaller Firms Lies In The Back-End

With more deals on earlier-stage platform technologies and compounds, the companies offering such assets need to take a rational approach to pricing – accepting a lot of potential back-end compensation – to get fair value, one analyst says.

DealWatch_1200x675

The controversy around US drug pricing dynamics is adding another dimension of difficulty to deal-making, says Vasilios Kofitsas of Back Bay Life Science Advisors, and an environment where established products may not be as safe an asset class as in the past should drive an increase in deals around emerging technology platforms and earlier-stage candidates.

This could prove a double-edged sword for smaller companies and start-ups, because assets backed by limited data often are assigned...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.